Klinik Araştırma
BibTex RIS Kaynak Göster

Relationship between Serum Fetuin-B Level and Metabolic Parameters in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Yıl 2025, , 75 - 80, 15.01.2025
https://doi.org/10.37990/medr.1496137

Öz

Aim: Fetuin-B, which is part of the fetuin family, has been demonstrated to be related with the emergence of insulin resistance. Here, we examined the relationship between metabolic parameters in treatment-naive patients with diabetes and fetuin B levels in serum.
Material and Method: Individuals aged 30-65 years old who were diagnosed with newly diagnosed diabetes mellitus, had no chronic disease history, and provided informed consent were enrolled in the study. The clinical parameters were examined.
Results: Forty recently diagnosed type 2 diabetic individuals and 43 controls were analyzed in this study. A significant difference was displayed for waist circumference, serum high-density lipoprotein, low-density lipoprotein, alanine transaminase, homeostatic model assessment for insulin resistance, high-sensitivity C-reactive protein, and carotid intima-media thickness (CIMT) between the two groups. The level of serum fetuin-B was determined to be statistically significantly reduced in diabetic patients compared to that in the serum of the controls. In the diabetic group, we showed a negative correlation between CIMT and fetuin-B (p=0.035).
Conclusion: Fetuin-B levels were considerably lower in recently diagnosed type 2 diabetics as equated with those in the control group who had normal glucose levels. Additionally, an inverse association between CIMT and fetuin-B levels among individuals with recently diagnosed type 2 diabetes mellitus.

Etik Beyan

Local ethics approval was obtained upon decision of 18.08.2015 No: 2 from the Non-Interventional Clinical Research Ethics Committee of Izmir Bozyaka Training and Research Hospital.

Kaynakça

  • Htay T, Soe K, Lopez-Perez A, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. Curr Cardiol Rep. 2019;21:45.
  • Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-8.
  • Darabian S, Hormuz M, Latif MA, et al. The role of carotid intimal thickness testing and risk prediction in the development of coronary atherosclerosis. Curr Atheroscler Rep. 2013;15:306.
  • Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the american society of echocardiography carotid intima-media thickness task force endorsed by the society for vascular. J Am Soc Echocardiogr. 2008;21:93-190. Erratum in: J Am Soc Echocardiogr. 2008;21:376.
  • Olivier E, Soury E, Ruminy P, et al. Fetuin-B, a second member of the fetuin family in mammals. Biochem J. 2000;350:589-97.
  • Liu JX, Zhai YH, Geng FS, et al. Molecular characterization and expression pattern of fetuin-B in gibel carp (Carassius auratus gibelio). Biochem Genet. 2008;46:620-33.
  • Yang F, Schwartz Z, Swain LD, et al. Alpha2-HS-glycoprotein: Expression in chondrocytes and augmentation of alkaline phosphatase and phospholipase A2 activity. Bone. 1991;12:7-15.
  • Chen H, Srinivas PR, Cong LN, et al. Alpha2-Heremans Schmid glycoprotein inhibits insulin-stimulated Elk-1 phosphorylation, but not glucose transport, in rat adipose cells. Endocrinology. 1998;139:4147-54.
  • Ohnishi T, Nakamura O, Arakaki N, Daikuhara Y. Effect of phosphorylated rat fetuin on the growth of hepatocytes in primary culture in the presence of human hepatocyte-growth factor. Evidence that phosphorylated fetuin is a natural modulator of hepatocyte-growth factor. Eur J Biochem. 1997;243:753-61.
  • Wang H, Zhang M, Bianchi M, et al. Fetuin (α2-HS-glycoprotein) opsonizes cationic macrophage-deactivating molecules. Proc Natl Acad Sci U S A. 1998;95:14429-34.
  • Almarashda O, Abdi S, Yakout S, et al. Hepatokines fetuin-A and fetuin-B status in obese Saudi patient with diabetes mellitus type 2. Am J Transl Res. 2022;14:3292-302.
  • Peter A, Kovarova M, Staiger H, et al. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans. Am J Physiol Endocrinol Metab. 2018;314:E266-73.
  • American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41:S13-27.
  • Li L, Spranger L, Stobäus N, et al. Fetuin-B, a potential link of liver-adipose tissue cross talk during diet-induced weight loss–weight maintenance. Nutr Diabetes. 2021;11:31.
  • Wang D, Liu Y, Liu S, et al. Serum fetuin-B is positively associated with intrahepatic triglyceride content and increases the risk of insulin resistance in obese Chinese adults: A cross-sectional study. J Diabetes. 2018;10:581-8.
  • Pasmans K, Goossens GH, Groenhuijzen E, et al. Fetuin B in white adipose tissue induces inflammation and is associated with peripheral insulin resistance in mice and humans. Obesity. 2024;32:517-27.
  • Xia X, Xue S, Yang G, et al. Association of serum fetuin-B with insulin resistance and pre-diabetes in young Chinese women: evidence from a cross-sectional study and effect of liraglutide. PeerJ. 2021;9:e11869.
  • Qu H, Qiu Y, Wang Y, et al. Plasma fetuin-B concentrations are associated with insulin resistance and first-phase glucose-stimulated insulin secretion in individuals with different degrees of glucose tolerance. Diabetes Metab. 2018;44:488-92.
  • Zhu J, Wan X, Wang Y, et al. Serum fetuin B level increased in subjects of nonalcoholic fatty liver disease: a case-control study. Endocrine. 2017;56:208-11.
  • El-Ashmawy HM, Ahmed AM. Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. Eur J Gastroenterol Hepatol. 2019;31:859-64.
  • Li Z, Lin M, Liu C, et al. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: Association and path analyses. Cytokine. 2018;108:145-50.
  • Yakout SM, Hussein S, Al-Attas OS, et al. Hepatokines fetuin A and fetuin B status in women with/without gestational diabetes mellitus. Am J Transl Res. 2023;15:1291-9.
  • Li Z, He C, Liu Y, et al. Association of fetuin-b with subclinical atherosclerosis in obese chinese adults. J Atheroscler Thromb. 2020;27:418-28.
  • Hou J, Deng Q, Liu S, et al. Plasma proteome profiling of patients with in-stent restenosis by tandem mass tag-based quantitative proteomics approach. Front Cardiovasc Med. 2022;9:793405.
Yıl 2025, , 75 - 80, 15.01.2025
https://doi.org/10.37990/medr.1496137

Öz

Kaynakça

  • Htay T, Soe K, Lopez-Perez A, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. Curr Cardiol Rep. 2019;21:45.
  • Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-8.
  • Darabian S, Hormuz M, Latif MA, et al. The role of carotid intimal thickness testing and risk prediction in the development of coronary atherosclerosis. Curr Atheroscler Rep. 2013;15:306.
  • Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the american society of echocardiography carotid intima-media thickness task force endorsed by the society for vascular. J Am Soc Echocardiogr. 2008;21:93-190. Erratum in: J Am Soc Echocardiogr. 2008;21:376.
  • Olivier E, Soury E, Ruminy P, et al. Fetuin-B, a second member of the fetuin family in mammals. Biochem J. 2000;350:589-97.
  • Liu JX, Zhai YH, Geng FS, et al. Molecular characterization and expression pattern of fetuin-B in gibel carp (Carassius auratus gibelio). Biochem Genet. 2008;46:620-33.
  • Yang F, Schwartz Z, Swain LD, et al. Alpha2-HS-glycoprotein: Expression in chondrocytes and augmentation of alkaline phosphatase and phospholipase A2 activity. Bone. 1991;12:7-15.
  • Chen H, Srinivas PR, Cong LN, et al. Alpha2-Heremans Schmid glycoprotein inhibits insulin-stimulated Elk-1 phosphorylation, but not glucose transport, in rat adipose cells. Endocrinology. 1998;139:4147-54.
  • Ohnishi T, Nakamura O, Arakaki N, Daikuhara Y. Effect of phosphorylated rat fetuin on the growth of hepatocytes in primary culture in the presence of human hepatocyte-growth factor. Evidence that phosphorylated fetuin is a natural modulator of hepatocyte-growth factor. Eur J Biochem. 1997;243:753-61.
  • Wang H, Zhang M, Bianchi M, et al. Fetuin (α2-HS-glycoprotein) opsonizes cationic macrophage-deactivating molecules. Proc Natl Acad Sci U S A. 1998;95:14429-34.
  • Almarashda O, Abdi S, Yakout S, et al. Hepatokines fetuin-A and fetuin-B status in obese Saudi patient with diabetes mellitus type 2. Am J Transl Res. 2022;14:3292-302.
  • Peter A, Kovarova M, Staiger H, et al. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans. Am J Physiol Endocrinol Metab. 2018;314:E266-73.
  • American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41:S13-27.
  • Li L, Spranger L, Stobäus N, et al. Fetuin-B, a potential link of liver-adipose tissue cross talk during diet-induced weight loss–weight maintenance. Nutr Diabetes. 2021;11:31.
  • Wang D, Liu Y, Liu S, et al. Serum fetuin-B is positively associated with intrahepatic triglyceride content and increases the risk of insulin resistance in obese Chinese adults: A cross-sectional study. J Diabetes. 2018;10:581-8.
  • Pasmans K, Goossens GH, Groenhuijzen E, et al. Fetuin B in white adipose tissue induces inflammation and is associated with peripheral insulin resistance in mice and humans. Obesity. 2024;32:517-27.
  • Xia X, Xue S, Yang G, et al. Association of serum fetuin-B with insulin resistance and pre-diabetes in young Chinese women: evidence from a cross-sectional study and effect of liraglutide. PeerJ. 2021;9:e11869.
  • Qu H, Qiu Y, Wang Y, et al. Plasma fetuin-B concentrations are associated with insulin resistance and first-phase glucose-stimulated insulin secretion in individuals with different degrees of glucose tolerance. Diabetes Metab. 2018;44:488-92.
  • Zhu J, Wan X, Wang Y, et al. Serum fetuin B level increased in subjects of nonalcoholic fatty liver disease: a case-control study. Endocrine. 2017;56:208-11.
  • El-Ashmawy HM, Ahmed AM. Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. Eur J Gastroenterol Hepatol. 2019;31:859-64.
  • Li Z, Lin M, Liu C, et al. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: Association and path analyses. Cytokine. 2018;108:145-50.
  • Yakout SM, Hussein S, Al-Attas OS, et al. Hepatokines fetuin A and fetuin B status in women with/without gestational diabetes mellitus. Am J Transl Res. 2023;15:1291-9.
  • Li Z, He C, Liu Y, et al. Association of fetuin-b with subclinical atherosclerosis in obese chinese adults. J Atheroscler Thromb. 2020;27:418-28.
  • Hou J, Deng Q, Liu S, et al. Plasma proteome profiling of patients with in-stent restenosis by tandem mass tag-based quantitative proteomics approach. Front Cardiovasc Med. 2022;9:793405.
Toplam 24 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Endokrinoloji
Bölüm Özgün Makaleler
Yazarlar

Canan Karan 0000-0002-1293-2046

Mehmet Çalan 0000-0002-5614-0710

Arif Yüksel 0000-0002-8568-5787

Oktay Bilgir 0000-0001-9579-0583

Giray Bozkaya 0000-0002-5756-5796

Emre Gezer 0000-0002-5340-6106

Yayımlanma Tarihi 15 Ocak 2025
Gönderilme Tarihi 5 Haziran 2024
Kabul Tarihi 9 Eylül 2024
Yayımlandığı Sayı Yıl 2025

Kaynak Göster

AMA Karan C, Çalan M, Yüksel A, Bilgir O, Bozkaya G, Gezer E. Relationship between Serum Fetuin-B Level and Metabolic Parameters in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Med Records. Ocak 2025;7(1):75-80. doi:10.37990/medr.1496137

 Chief Editors

Assoc. Prof. Zülal Öner
Address: İzmir Bakırçay University, Department of Anatomy, İzmir, Turkey

Assoc. Prof. Deniz Şenol
Address: Düzce University, Department of Anatomy, Düzce, Turkey

Editors
Assoc. Prof. Serkan Öner
İzmir Bakırçay University, Department of Radiology, İzmir, Türkiye

E-mail: medrecsjournal@gmail.com

Publisher:
Medical Records Association (Tıbbi Kayıtlar Derneği)
Address: Orhangazi Neighborhood, 440th Street,
Green Life Complex, Block B, Floor 3, No. 69
Düzce, Türkiye
Web: www.tibbikayitlar.org.tr

Publication Support: 

Effect Publishing & Agency
Phone: + 90 (540) 035 44 35
E-mail: info@effectpublishing.com
Address: Akdeniz Neighborhood, Şehit Fethi Bey Street,
No: 66/B, Ground floor, 35210 Konak/İzmir, Türkiye
web: www.effectpublishing.com